USP Drug Quality Pilot Program Underway in Sub-Saharan Africa - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

USP Drug Quality Pilot Program Underway in Sub-Saharan Africa


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

On Apr. 18, 2011, scientists from the national laboratories of five African nations gathered in Accra, Ghana, to take part in a week of technical training put on by the US Pharmacopeia (USP) that will teach them how to detect substandard and counterfeit medicines.

USP is providing participants from Ethiopia, Ghana, Kenya, Senegal, and Sierra Leone with pharmaceutical reference standards, documentary standards, and technical writing training in an effort to improve help the quality of those countries’ medicines.  The instruction is a part of a pilot Technical Assistance Program (TAP) that was introduced earlier this year and funded by USP.

USP developed TAP based on feedback from participants about topics they wanted to see addressed most.  National laboratories in these countries often have to rely on unreliable or outdated standards to analyze medicines. The laboratories also may not be equipped to offer analysts the scientific training needed to appropriately analyze medicines.

As a result, accurate outcomes may not be obtained when questionable substances are tested. “Having a team of scientists trained in essential analytical techniques is a fundamental aspect of a well-functioning regulatory system that protects domestic drug supply,” said Patrick Lukulay, director of the PQM program in a USP press release.

The objective of the training is to improve the technical competence of the scientists and familiarize participants with information contained in the USP-NF, including how to use the information, according to the USP release.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here